Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma

被引：4
|
作者：
Shimabukuro-Vornhagen, A. [1 ]
Josting, A. [1 ]
Huebel, K. [1 ]
Scheid, C. [1 ]
Dietlein, M. [1 ]
Engert, A. [1 ]
Schnell, R. [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8615
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Yttrium-90 (Ytracis) Labelled Ibritumomab Tiuxetan (Zevalin) in Patients with Relapsed or Refractory B-Cell non-Hodkin's Lymphoma
    Lipp, R. W.
    Piswanger-Soelkner, J. C.
    Dorda, A. F.
    Brezinschek, R. I.
    Lackner, H.
    Linkesch, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S93 - S93
  • [32] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphorna not appropriate for autologous stem-cell transplantation
    Morschhauser, Franck
    Illidge, Tim
    Huglo, Damien
    Martinelli, Giovanni
    Paganelli, Giovanni
    Zinzani, Pier Luigi
    Rule, Simon
    Liberati, Anna Marina
    Milpied, Noel
    Hess, Georg
    Stein, Harald
    Kalmus, Joachim
    Marcus, Robert
    BLOOD, 2007, 110 (01) : 54 - 58
  • [33] Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma
    Othman, Tamer
    Lowsky, Robert
    Richman, Carol
    Hoeg, Rasmus
    Abedi, Mehrdad
    Tuscano, Joseph
    BONE MARROW TRANSPLANTATION, 2023, 58 (10) : 1143 - 1145
  • [34] Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma
    Tamer Othman
    Robert Lowsky
    Carol Richman
    Rasmus Hoeg
    Mehrdad Abedi
    Joseph Tuscano
    Bone Marrow Transplantation, 2023, 58 : 1143 - 1145
  • [35] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Palumbo, B.
    Sabalich, I.
    Falcinelli, F.
    Capponi, M.
    Martelli, M.
    Palumbo, R.
    Sinzinger, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
  • [36] Yttrium-90 ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (Zevalin-BEAM) conditioning regimen in relapsed aggressive non-Hodgkin lymphoma
    Tan, S. M.
    Lau, N. S.
    Lim, S. M.
    Zanapiah, M.
    Chang, K. M.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S440 - S441
  • [37] The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
    Witzig, TE
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 74 - 78
  • [38] High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma
    Provencio, Mariano
    Fayad, Luis E.
    MEDICINA CLINICA, 2008, 130 (02): : 60 - 65
  • [39] Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma
    Kriegsmann, Katharina
    Rieger, Michael
    Schwarzbich, Mark-Alexander
    Sitter, Soeren
    Kriegsmann, Mark
    Bruckner, Thomas
    Hensel, Manfred
    Ho, Anthony Dick
    Witzens-Harig, Mathias
    Wuchter, Patrick
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) : 12 - 20
  • [40] High-dose chemotherapy and autologous stem cell transplantation for Korean patients with relapsed or refractory Hodgkin's lymphoma
    Park, K.
    Yoon, D.
    Kim, S.
    Huh, J.
    Park, C.
    Lee, S.
    Park, S.
    Ahn, Y.
    Jo, J.
    Suh, C.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S445 - S445
12345